<DOC>
	<DOCNO>NCT00761449</DOCNO>
	<brief_summary>The aim study investigate efficacy lenalidomide high risk MDS AML chromosome 5 aberration .</brief_summary>
	<brief_title>Lenalidomide High-risk MDS AML With Del ( 5q ) Monosomy 5</brief_title>
	<detailed_description>Previous study show immunomodulatory drug lenalidomide effective treatment low risk MDS del ( 5q ) . Treatment subgroup MDS patient result 67 % major erythroid response 45 % complete cytogenetic response . We therefore intend test efficacy lenalidomide group high-risk patient ineligible conventional chemotherapy dismal prognosis . The patient must karyotype include del ( 5q ) patient karyotype include monosomy 5 also eligible . We hypothesize hight risk MDS AML patient chromosomal aberration del ( 5q ) affect lenalidomide effect .</detailed_description>
	<mesh_term>Monosomy</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must &gt; 18 year age time sign informed consent form MDS IPSS Int2 High karyotype include del ( 5q ) monosomy 5 confirm FISH ( use LSI EGR1/D5S23 , D5S721 FISH probe ) Acute myeloid leukemia karyotype include del ( 5q ) monosomy 5 confirm FISH ( use LSI EGR1/D5S23 , D5S721 FISH probe ) Patients could include : At diagnosis consider eligible induction chemotherapy Refractory induction therapy Relapse induction chemotherapy lead CR consider eligible reinduction Relapse allogeneic stem cell transplantation consider suitable reinduction chemotherapy conventional relapse therapy . Subject sign informed consent document . Women childbearing potential , WCBP , must agree practice complete abstinence heterosexual intercourse use two method contraception begin 4 week prior start study medication , study medication 4 week last dose study medication . WCBP must two negative serum urine pregnancy test prior start study drug . WCBP must agree pregnancy test weekly first 4 week every 4 week study medication 4 week last dose study medication . Males ( include vasectomy ) must use barrier contraception ( latex condom ) engage reproductive sexual activity WCBP study medication 4 week last dose study medication . Pregnant lactating female . Prior therapy lenalidomide Patients eligible curative treatment Expected survival less two month . Acute promyelocytic leukemia ( APL ) Absolute peripheral blast count &gt; 30,000/mm3 Central nervous system leukemia Serum biochemical value follow Serum creatinine &gt; 2.0 mg/dL ( 177 micromol/L ) Serum aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 1.5 mg/dL ( 26 micromol/L ) Prior allergic reaction thalidomide Uncontrolled systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>monosomy 5</keyword>
	<keyword>del5q</keyword>
</DOC>